AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01940432 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: pelvic floor muscle training group
Description: Procedure:first,identify anal sphincter/feel anus, and try to raise it from chair (without adding abdominal, thigh, and buttock muscles) with a position of sitting; second, identify levator ani and try to raise vagina from chair (without adding abdominal, thigh, and buttock muscles) with a position of Sitting, bent forward, elbows on knees; third, contract levator ani with a position of sitting, lying, and standing; fourth, contract anal sphincter with a position of sitting, lying, and standing. Length of Treatment and the treatment sessions are the same as treatment group.
Study NCT01169012 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Clofarabine
Description: Intravenous Clofarabine (10mg/m2) Oral clofarabine (30mg/m2) Cimetidine (800mg)
Study NCT03411083 — intervention group
Intervention type: PROCEDURE
Intervention: Total or unicompartmental knee replacement
Description: Fast-track Knee replacement surgery including same day surgery
Study NCT04365231 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine and azithromycin treatment
Description: hydroxychloroquine 10-day course of hydroxychloroquine 200 mg tablet three times a day. To be taken orally.~- azithromycin 5-day course of azithromycin 250 mg tablet twice a day on the first day of treatment, then once a day the 4 following days.
Study NCT04365231 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional management of patients
Description: conventional management of patients
Study NCT04365231 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional management of patients
Description: conventional management of patients
Study NCT04116736 — intervention group
Intervention type: DEVICE
Intervention: ACUVUE® OASYS with Transitions™
Description: JJVC Marketed Contact Lens
Study NCT04116736 — intervention group
Intervention type: DEVICE
Intervention: Silicone Hydrogel Contact Lens
Description: Any reusable spherical silicone hydrogel brand that is approved and marketed in the country conducting the study.
Study NCT03574662 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Frailty assessment
Description: This assessment consists of a combination of gait speed measurement via infrared sensors as well as a grip strength assessment. Patients will then attend cardiac rehabilitation for an abbreviated six week program.
Study NCT03574662 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality of life assessment
Description: This assessment consists of two questionnaires, Kansas City Cardiomyopathy Questionnaire and Minnesota Living with Heart Failure questionnaire. Patients will then attend cardiac rehabilitation for an abbreviated six week program.
Study NCT01492153 — intervention group
Intervention type: DRUG
Intervention: biphasic human insulin
Description: NovoLet® device delivering human insulin. Selection of drug and timing of dose for each patient was at the discretion of the investigator
Study NCT01492153 — intervention group
Intervention type: DRUG
Intervention: isophane human insulin
Description: NovoLet® device delivering human insulin. Selection of drug and timing of dose for each patient was at the discretion of the investigator
Study NCT01492153 — intervention group
Intervention type: DRUG
Intervention: human soluble insulin
Description: NovoLet® device delivering human insulin. Selection of drug and timing of dose for each patient was at the discretion of the investigator
Study NCT03635099 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (fasted)
Description: Placebo matching BI 730357 taken orally once daily as a film-coated tablet in the morning while fasted for 12 weeks in period 1 followed by the same treatment for 12 weeks in period 2 (total treatment period of 24 weeks).
Study NCT03635099 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 25 mg (fasted)
Description: 25 milligram (mg) BI 730357 taken orally once daily as a film-coated tablet in the morning while fasted for 12 weeks in period 1 followed by the same treatment for 12 weeks in period 2 (total treatment period of 24 weeks).
Study NCT03635099 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 50 mg (fasted)
Description: 50 milligram (mg) BI 730357 taken orally once daily as a film-coated tablet in the morning while fasted for 12 weeks in period 1 followed by the same treatment for 12 weeks in period 2 (total treatment period of 24 weeks).
Study NCT03635099 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 100 mg (fasted)
Description: 100 milligram (mg) BI 730357 taken orally once daily as a film-coated tablet in the morning while fasted for 12 weeks in period 1 followed by the same treatment for 12 weeks in period 2 (total treatment period of 24 weeks).
Study NCT03635099 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 200 mg (fasted)
Description: 200 milligram (mg) BI 730357 taken orally once daily as a film-coated tablet in the morning while fasted for 12 weeks in period 1 followed by the same treatment for 12 weeks in period 2 (total treatment period of 24 weeks).
Study NCT03635099 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (fed)
Description: 4 film-coated tablets of matching Placebo were taken orally in the morning with a meal and 2 film-coated tablets of matching Placebo were taken orally in the evening with a meal for 12 weeks.
Study NCT03635099 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 400 mg once daily (fed)
Description: 4 film-coated tablets of 100 milligram (mg) BI 730357 (400 mg in total) were taken orally in the morning with a meal and 2 film-coated tablets of matching Placebo were taken orally in the evening with a meal for 12 weeks.
Study NCT03635099 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 200 mg twice daily, 400 mg total (fed)
Description: 2 film-coated tablets of 100 milligram (mg) BI 730357 were taken orally with a meal in the morning and evening (twice daily; total daily dosage: 400 mg) for 12 weeks.
Study NCT02993185 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Your Move
Description: Your Move (YM) is an interactive sex education intervention. Groups of girls are randomly assigned to YM or Eat Smart (ES), a control interactive nutrition education intervention. Each program consist of seven 75-minute sessions, and each session contains 60 minutes of facilitator-led discussion, video clips, activities, and games as well as 15 minutes of personal reflection time during which girls practice the decision making skills they have learned. Participants complete online surveys about their attitudes, knowledge, and behavior related to food and nutrition and relationships and sex at baseline and also 3 months after the program ends.
Study NCT02993185 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Eat Smart
Description: Eat Smart (ES) is an interactive nutrition education intervention. Groups of girls are randomly assigned to ES or Your Move, an interactive sex education intervention. Each program consist of seven 75-minute sessions, and each session contains 60 minutes of facilitator-led discussion, video clips, activities, and games as well as 15 minutes of personal reflection time during which girls practice the decision making skills they have learned. Participants complete online surveys about their attitudes, knowledge, and behavior related to food and nutrition and relationships and sex at baseline and also 3 months after the program ends.
Study NCT03724331 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Light Physical Activity 1
Description: Light (mild) physical activity program that corresponds with normal every day activities of daily living (\< 3.0 metabolic equivalents, METs), with a time commitment starting at 5 minutes a day 5 days a week gradually increasing to 30 minutes a day 5 days a week as you are able by week 6 as guided by your Registered Nurse researcher.~The program begins approximately within one week after discharge from the hospital with the physical activity program starting approximately within the first week post-discharge from the hospital.
Study NCT03724331 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Light Physical Activity 2
Description: Light (mild) physical activity program that corresponds with normal every day activities of daily living (\< 3.0 metabolic equivalents, METs), with a time commitment starting at 5 minutes a day 5 days a week gradually increasing to 30 minutes a day 5 days a week as you are able by week 6 as guided by your Registered Nurse researcher.~The program begins approximately within one week after discharge from the hospital with the physical activity program starting approximately 7 weeks post-discharge from the hospital.
Study NCT03724331 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Support Education Activity
Description: Participate in a supportive cancer-related education activity including a direct 10 - 15 minute phone conversation with a Registered Nurse researcher each week for 6-weeks after returning home from the hospital. Wear a pedometer each day of the study.~Recording pedometer steps in the daily diary each day.
Study NCT04425590 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DLBS1033
Description: DLBS 1033 490 mg tablet 3 times daily
Study NCT04425590 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: Aspirin 100 mg tablet once daily
Study NCT04425590 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Aspirin 100 mg tablet once daily
Study NCT04425590 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Statin
Description: Atorvastatin 20 mg tablet once daily
Study NCT04425590 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Statin
Description: Atorvastatin 20 mg tablet once daily
Study NCT04425590 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vit B12
Description: Vit B12 100 mg tablet three times daily
Study NCT04425590 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vit B12
Description: Vit B12 100 mg tablet three times daily
Study NCT02521363 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: KIBUR MICRODEVICE
Description: This device contains 16 reservoirs, each with a unique single agent or drug combination in microdose amounts of less than one millionth of a systemic patient dose. The device is implanted directly into the tumor during a biopsy procedure, and remains in situ for \~24 hours.
Study NCT02521363 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anthracycline and taxane based chemotherapy
Description: Conventional, standard of care neoadjuvant chemotherapy delivered irrespective of device readout
Study NCT00669318 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: alemtuzumab
Study NCT00669318 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Study NCT00669318 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pentostatin
Study NCT00669318 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sargramostim
Study NCT00409279 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Information, counseling and support
Description: individual-family consultation, support group, and ad hoc consultation
Study NCT02822430 — intervention group
Intervention type: OTHER
Intervention: Pain scales
Description: * Visual analogic scale of pain~* Pain behaviour scale~* Short-FormHealth Survey (SF-36)~* Clinical Global impression~* Mini International Neuropsychiatric Interview (MINI)
Study NCT01655953 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High NaCl + KHCO3
Description: 7.7 mmol Na/kgBW/d + 90 mmol KHCO3
Study NCT01655953 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control: high NaCl
Description: 7.7 mmol Na/kgBW/d
Study NCT04596839 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remdesivir
Description: Remdesivir INN 100 mg lyophilized powder for infusion
Study NCT04596839 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard of Care
Description: Standard of Care Treatment for COVID-19 Infection
Study NCT03711422 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afatinib
Description: 40mg daily
Study NCT03161041 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cytoreductive surgery combined with HIPEC
Description: Procedure/Surgery: Cytoreductive surgery combined with HIPEC (Oxaliplatin 360 mg/m2).
Study NCT03161041 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab and HIPEC (Oxaliplatin 360 mg/m2).
Description: bevacizumab and HIPEC (Oxaliplatin 360 mg/m2).
Study NCT00447096 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Repetitive Transcranial Magnetic Stimulation (rTMS)
Description: Repetitive transcranial magnetic stimulation (rTMS).
Study NCT00447096 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive Transcranial Magnetic Stimulation (rTMS)
Description: Repetitive transcranial magnetic stimulation (rTMS).
Study NCT02136459 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Small Tube size
Description: An endotracheal tube of size 6.5 in females and 7.0 in males was used for endotracheal intubation of patients undergoing thyroid surgery
Study NCT02136459 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Large Tube size
Description: An endotracheal tube of size 7.5 in females and 8.0 in males was used for endotracheal intubation of patients undergoing thyroid surgery
Study NCT03065686 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: identification of genetic factors
Description: Clinical questionnaire and analysis of genetic data obtained by exome high-throughput sequencing
Study NCT04974229 — intervention group
Intervention type: OTHER
Intervention: In line with the Dutch guideline for non-specific low back pain, Standard usual care for non-specific low back pain was applied.
Description: In line with the Dutch guideline for non-specific low back pain, Standard usual care or non-specific low back pain was applied.
Study NCT02277275 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: BCAA
Description: Branched chain amino acid(BCAA) pills will be provided to subjects 0.15g/kg of body weight per day for six months
Study NCT02277275 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be provided to the other two arms for six months
Study NCT01967680 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non-sedation for intubated, mechanically ventilated patients
Study NCT01967680 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Controlgroup, sedation with daily wake-up trial
Study NCT01814410 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intravenous ethanol placebo plus nicotine infusions
Description: nicotine infusions: 1) placebo; 2) nicotine 0.5 mg/70 kg; 3) nicotine 1.0 mg/70 kg
Study NCT01814410 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intravenous ethanol 40mg% plus nicotine infusions
Description: nicotine infusions: 1) placebo; 2) nicotine 0.5 mg/70 kg; 3) nicotine 1.0 mg/70 kg
Study NCT01814410 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intravenous ethanol 100mg% plus nicotine infusions
Description: nicotine infusions: 1) placebo; 2) nicotine 0.5 mg/70 kg; 3) nicotine 1.0 mg/70 kg
Study NCT01810562 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Specific treatment in addition to standard stroke care
Description: Stimulation of both the affected side and not affected side. Treatment twice per day for three months. Unperturbed side always stimulated first.~Isstimulering achieved by an ice cube melted on each of the affected ektremitetene evenly distributed.~Brushing on thin clothing or directly on the skin, 10 times rapidly for each location. On the back of m. deltoideus from right to left side of the body, laterally along the humerus, frontally, along the radius / ulna laterally, frontal and dorsal palm, along the femur first laterally and frontally, along the tibia / fibula laterally, frontally and the footplate dorsal side.~Scrolling with spiked ball over the same area as brushing for two minutes evenly.~Firm pressure for two minutes evenly in the same area.
Study NCT00091468 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Transdermal nicotine patch
Description: double-blind phase: 5mg for 1 week, 10mg for 2 weeks, 15mg for 23 weeks open label phase: 5mg for 1 week, 10mg. for 2 weeks, 15mg. for 23 weeks taper down: 10mg. for 2 weeks, 5mg. for 1 week
Study NCT00091468 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo transdermal patch
Description: placebo patch, 5mg for 1 week, 10mg for 2 weeks, 15mg for 23 weeks
Study NCT03128450 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: human neural stem cell
Description: human neural stem cell: 100ul/vessel，2 vessel/one bag，≥2×10 6cells/vessel
Study NCT04194489 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FMF Connect
Description: The FMF Connect intervention includes cloud infrastructure and an innovative, multilayered mobile app. It incorporates tailored content for parents/caregivers of children (ages 3-12) with FASD or PAE. The app integrates five main components: 1) Dashboard; 2) Learning Modules; 3) Family Forum; 4) Library; and 5) Notebook. Weekly emails are also sent to support motivational engagement.
Study NCT02402946 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Biofeedback
Study NCT02402946 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02020369 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Coagulation Factor VIIa (Recombinant)
Description: A cross over design to assess the efficacy of 2 separate dose regimens (75µg/kg and 225 µg/kg) of Coagulation Factor VIIa (Recombinant) for the treatment of bleeding episodes in hemophilia A or B patients with inhibitors to Factor VIII/IX
Study NCT04064203 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oral glucose tolerance test
Description: 50 grams OGTT
Study NCT04064203 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clamp experiment
Description: insulin-induced hypoglycaemic clamp followed by an 50 grams OGTT
Study NCT02751112 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Predictor' kit
Description: Realization of the Predictor' kit on the blood of donor of HSC, in the frame of a graft, to predict a aGvH reaction on recipient patient.
Study NCT02397941 — intervention group
Intervention type: OTHER
Intervention: Ultrasound
Description: ultrasound measures
Study NCT03711422 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afatinib
Description: 160mg for 3 days every 3 weeks
Study NCT01000987 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: varenicline
Description: 1mg/day or 2 mg/day Subjects are at steady state medication levels. They are participating during the 4-week medication period of our ongoing study, NCT00580645.
Study NCT01000987 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study NCT00687986 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: stereotactic radiotherapy
Description: Either 3 fractions of 20 Gray or 5 fractions of 12 Gy
Study NCT00687986 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: primary surgery
Description: an anatomical surgical resection with lymph node dissection
Study NCT01439243 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil
Description: 10 mg Tablet
Study NCT01439243 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aricept®
Description: 10 mg Tablet
Study NCT01289327 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sedation with Propofol or Midazolam+Alfentanil for FFB
Description: Sedation was started with intravenous injection of a bolus of 2-4 mg midazolam and 0.5 mg alfentanil or 20-50 mg propofol. It was maintained with intermittent boluses of 1-3 mg intravenous midazolam or 0.5 mg intravenous alfentanil, according to clinical judgment, or with boluses of 10-20 mg intravenous propofol, administered at short intervals (\~2 minutes) or according to clinical judgment.
Study NCT01411319 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Lattice Extreme Ablative Dose Radiation Therapy
Description: 12 - 14 Gy dose pipes in 1 fraction to the multiparametric MRI defined gross tumor volumes (GTV) on Day 1.
Study NCT01411319 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Standard IMRT
Description: 76 Gy in 38 fractions (2 Gy daily) of Standard Intensity-modulated radiation therapy (IMRT) starting on Day 2 for 7.5 weeks.
Study NCT04624048 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: COVID-19 survey
Description: Participants should complete a survey to analyze the impact of COVID-19 on University population.
Study NCT01255904 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chloral Hydrate
Description: Oral chloral hydrate 50 mg/kg
Study NCT01255904 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Intranasal dexmedetomidine 3 mcg/kg
Study NCT03834324 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FES
Description: Functional Electrical Stimulation during cycling with Virtual Reality Feedback
Study NCT02946853 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Atrioventricular junctional (AVJ) ablation
Description: RF energy delivery to AV node to create complete AV block
Study NCT02946853 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cardiac resynchronization therapy - defibrillator
Description: Insertion of device capable of providing biventricular pacing and cardiac defibrillation